Table 1.
The Patient’s Characteristics and Clinical Outcome of CD20 Expression Status
| Parameters | CD20 Negative (N = 41) N (%) | CD20 Positive (N = 11) N (%) | p-value |
|---|---|---|---|
| Gender | |||
| Male (n = 30) | 24 (58.5) | 6 (54.5) | 0.812 |
| Female (n = 22) | 17 (41.5) | 5 (45.5) | |
| Age at diagnosis (years) | |||
| ≤10 (n = 4) | 3 (7.3) | 1 (9.1) | |
| 11-25 (n = 18) | 16 (39.0) | 2 (18.2) | |
| 26-40 (n = 20) | 15 (36.6) | 5 (45.5) | 0.498 |
| 41-55 (n = 4) | 2 (4.9) | 2 (18.2) | |
| >55 (n = 6) | 5 (12.2) | 1 (9.1) | |
| Histopathological classification (n = 42)* | |||
| Nodular sclerosis (n = 30) | 23 (71.9) | 7 (70.0) | |
| Mixed cellularity (n = 10) | 8 (25.0) | 2 (20.0) | 0.657 |
| Lymphocyte-rich (n = 2) | 1 (3.1) | 1 (10.0) | |
| Albumin** < 40g/L | |||
| Yes (n = 33) | 29 (70.7) | 4 (36.4) | 0.042 |
| No (n = 19) | 12 (29.3) | 7 (63.6) | |
| White Blood Cell Count** > 15×109/L | |||
| Yes (n = 12) | 9 (22.0) | 3 (27.3) | 0.495 |
| No (n = 40) | 32 (78.0) | 8 (72.7) | |
| Hemoglobin** < 10.5g/dl | |||
| Yes (n = 24) | 19 (46.3) | 5 (45.5) | 0.958 |
| No (n = 28) | 22 (53.7) | 6 (54.5) | |
| Lymphocyte count** < 0.6×109/L | |||
| Yes (n = 5) | 4 (9.8) | 1 (9.1) | 0.717 |
| No (n = 47) | 37 (90.2) | 10 (90.9) | |
| Urea** (n = 48) | |||
| Low (n = 23) | 19 (46.3) | 4 (36.4) | |
| Normal (n = 25) | 19 (46.3) | 6 (54.5) | 0.839 |
| High (n = 4) | 3 (7.4) | 1 (9.1) | |
| C-reactive protein (n = 39)* | |||
| Normal (n = 4) | 3 (10.0) | 1 (11.1) | 0.667 |
| High (n = 35) | 27 (90.0) | 8 (88.9) | |
| Disease stage (n = 40)* | |||
| Favorable early stage (n = 6) | 4 (13.3) | 2 (20.0) | 0.861 |
| Unfavorable early stage (n = 5) | 4 (13.3) | 1 (10.0) | |
| Advanced stage (n = 29) | 22 (73.4) | 7 (70.0) | |
| Ann-Arbor stage system (n = 39)* | |||
| Stage I (n = 2) | 1 (3.3) | 1 (11.1) | |
| Stage II (n = 8) | 7 (23.3) | 1 (11.1) | 0.716 |
| Stage III (n = 13) | 10 (33.3) | 3 (33.3) | |
| Stage IV (n = 16) | 12 (40.0) | 4 (44.4) | |
| Chemotherapy protocol (n = 49)* | |||
| No treatment received (n = 18) | 16 (41.0) | 2 (20.0) | |
| ABVD (n = 28) | 22 (56.4) | 6 (60.0) | 0.085 |
| Other than ABVD (n = 3) | 1 (2.6) | 2 (20.0) | |
| Response to chemotherapy (n = 25)* | |||
| Complete remission (n = 18) | 14 (70.0) | 4 (80.0) | |
| Partial remission (n = 1) | 1 (5.0) | 0 (0.0) | 0.841 |
| Relapse (n = 6) | 5 (25.0) | 1 (20.0) | |
| Bulky disease*** (n = 42)* | |||
| Yes (n = 2) | 1 (3.2) | 1 (9.1) | 0.460 |
| No (n = 40) | 30 (96.8) | 10 (90.9) | |
| B-symptoms (n = 45)* | |||
| Yes (n = 31) | 23 (65.7) | 8 (80.0) | 0.327 |
| No (n = 14) | 12 (34.3) | 2 (20.0) | |
Notes: *Including some study participants because of missing data for others. **All laboratory parameters were measured at baseline prior to the initiation of any treatment. ***“bulky disease” refers to large tumor masses defined as either a lymph node/mass ≥ 10 cm or a mediastinal mass exceeding 1/3 of the thoracic diameter at T5-T6 level.